Global Pain Therapeutics Market – Comprehensive Overview of Marketed and Pipeline Products, Opportunities, Challenges, Market Size and Key Players

The neuropathic pain market is the most valuable segment within the pain indications and was valued at $10.8bn in 2020 globally. It is forecast to reach $25.2bn by 2027 at a compound annual growth rate (CAGR) of 12.9%. The launch of different late-stage pipeline products throughout the forecast period will contribute heavily to the growth expected in the neuropathic pain market.

The pain therapeutics market is highly genericized with a wide range of treatment options available for pain indications. There are currently 12,048 marketed pain products globally. Mixed Pain products lead the group with 7,715 products approved, followed by Neuropathic Pain with 5,545 approved drugs and lastly Nociceptive Pain with 4,036 approved products.

The main focus for development in the pipeline is drugs for neuropathic pain indications. There are currently 315 pain therapeutics in development globally. Neuropathic pain therapies lead with 138 pipeline agents, followed by mixed pain and nociceptive pain with 96 and 81 drugs, respectively. The majority of products in development are in Phase II, with 137 products in the pipeline, followed by 106 products in Phase I and 55 in Phase III.

Alessio Brunello, Managing Pharma Analyst at GlobalData, comments: “The Innovation in the pain market over the last decade has been limited to new drug delivery systems, new extended-release formulations, and the repositioning of anticonvulsant and antidepressant therapeutics for difficult-to-treat pain conditions. Despite the improvements in symptom relief offered by new treatments and delivery systems, the pain market still has significant unmet needs. Opioids remain the most effective modes of treatment. However, because of their abuse potential, they are typically administered for chronic pain conditions. Furthermore, there is a significant lack of therapeutics that provide adequate relief for chronic pain types. This has resulted in regulatory changes, with the FDA employing tighter restrictions regarding the prescription and labeling of painkillers, as well as actively encouraging the development of novel analgesics.

“Chronic pain represents one of the most important public health problems in terms of the number of patients afflicted and healthcare cost. Most patients with chronic pain are treated with medications as the mainstay of therapy, yet most medically treated patients continue to report ongoing pain. Existing pain medications have significant limitations and adverse events including tolerance, dependence, gastrointestinal dysfunction, cognitive impairment, and a narrow therapeutic window, making the search for novel analgesics even more important.”


Pain is a multifaceted disorder that can be classified in a multitude of ways. Pain can be classified based on physiology, intensity, temporal characteristics, type of tissue affected, and syndrome. For the scope of this report, GlobalData will use the time course classification, with the main focus on chronic pain.

This report assesses:

– Physician perceptions on Pain Therapeutics usage in clinical practice Globally.

– Global Pain Therapeutics main classes Marketed products and main targets Pipeline products.

– Opportunities and Challenges

– Market analysis and Forecast

– Unmet Needs

– Key Players

The report combines information obtained from secondary sources and primary research with specialists and physicians

GlobalData’s Global Pain Therapeutics Market Overview report combines primary research from a cross-specialty panel of experts with in-house analyst expertise to provide an assessment of the development landscape.

Components of the slide deck include primary and secondary research:

– Quotes from key opinion leaders

– Summary of Pain Therapeutics product definitions and classifications

– Overview of key classes of Pain Therapeutics marketed products and key targets for pipeline Pain products

– Trends in Global Pain Therapeutics market

– Call-outs of key information and details

– Insight from GlobalData’s specialist healthcare analysts

Key Highlights

The Pain Therapeutics Market Is Highly Genericized

The Neuropathic Pain Market Is the Most Valuable Segment Within the Pain Indications

Innovation in the Pain Market Is Limited to New Drug Delivery Systems and New Formulations

The Main Focus for Development in the Pipeline Is Drugs for Neuropathic Pain Indications

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Pain Therapeutics.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Pain Therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned


Eli Lilly





Table of Contents

Table of Contents

1. Preface

1.1. Abbreviations

1.2. Related Reports

2. Executive Summary

2.1. Key Findings

3. Pain Overview

3.1. What is Pain?

3.2. Pain Classification

3.3. Acute Pain

3.4. Transitional Pain

3.5. Chronic Pain

4. Trends

4.1. Industry Trends

5. Clinical Trials

5.1. Pain Therapeutics in Clinical Trials

5.2. Pain Therapeutics Clinical Trials by Region

5.3. Pain Therapeutics Clinical Trials by Leading Sponsors

5.4. Pain Therapeutics in Clinical Trials – Challenges

5.5. Pain Therapeutics in Clinical Trials – Opportunities

6. Marketed Products

6.1. Marketed Global Pain Products

6.2. NSAIDs and COX-2 inhibitors

6.3. Opioids

6.4. Antidepressants and Anticonvulsants

7. Pipeline Products

7.1. Global Pain Therapeutics Pipeline Products

7.2. Beta Nerve Growth Factor Target

7.3. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Type I Receptor Target

7.4. Neurotensin Receptor 1 Target

8. Market Analysis

8.1. Mixed Pain Market Analysis and Forecast

8.2. Neuropathic Pain Market Analysis and Forecast

8.3. Nociceptive Pain Market Analysis and Forecast

8.4. Top 10 Deals in the Pain Therapeutics Space

8.5. H1 2021 Deals in the Pain Therapeutics Space

8.6. H2 2020- H1 2021 Mergers and Acquisitions in the Pain Therapeutics Space

9. Opportunities, Challenges, and Unmet Needs

9.1. Global Pain Therapeutics – Opportunities

9.2. Global Pain Therapeutics – Challenges

9.3. Global Pain Therapeutics Unmet Needs – Gap Analysis

10. Key Players

10.1. Pfizer

10.2. Eli Lilly

10.3. Allergan

10.4. Teva

10.5. Viatris

10.6. Novartis

11. Appendix

11.1. Bibliography

11.2. Primary Research

11.3. About the Authors

11.4. About GlobalData

11.5. Contact Us

11.6. Disclaimer


Discounts available for multiple purchases.
+44 20 7947 2745

Join our mailing list

Saved reports